Cancer
Novartis agrees Gleevec patent deal
May 19, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Gleevec, India, Novartis, Sun Pharma, patent
Novartis has settled patent litigation with Sun Pharmaceutical Industries in the US, paving the way for the Indian company’s subsidiary …
MedImmune signs Incyte oncology deal
May 15, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Incyte, MedImmune, oncology
MedImmune, the global biologics R&D arm of AstraZeneca, is to put one of its oncology immunotherapies into development in combination …
NICE: no early Zytiga use
May 14, 2014Sales and Marketing Cancer, Janssen, NHS, NICE, Zytiga, johnson, prostate
Janssen has criticised NICE’s decision not to recommend Zytiga on the NHS at an earlier stage in the prostate cancer …
AstraZeneca begins lung cancer trial
May 9, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, MEDI4736, NSCLC, lung cancer
AstraZeneca, currently at the centre of a £63 billion bid from US giant Pfizer, has begun a late-stage trial of …
Global cancer drug spend slows
May 7, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, IMS, spending
Spending on cancer drugs worldwide is slowing, according to a new report from the IMS Institute for Healthcare Informatics. The …
US cancer docs warn of rising drug prices
May 7, 2014Research and Development, Sales and Marketing ASCO, Cancer, NICE, Obama, US, United States, republicans
American cancer doctors are warning that the rising price of oncology medicines is making it unaffordable for the country’s healthcare …
FDA approves Zykadia for late-stage lung cancer
April 30, 2014Research and Development, Sales and Marketing Cancer, FDA, Novartis, lung, zykadia
Novartis’ ‘breakthrough’ drug Zykadia has been approved by the FDA to treat lung cancer patients with a particular genetic mutation. …
Cancer Research funding to be doubled
April 30, 2014Research and Development, Sales and Marketing CRUK, Cancer, brain, breast, funding, lung
Cancer Research UK is to increase its research funding by 50% over the next decade as part of a new strategy …
Mekinist shown green light by CHMP
April 28, 2014Sales and Marketing CHMP, Cancer, GSK, mekinist, oncology, trametinib
GlaxoSmithKline’s melanoma drug Mekinist is virtually nailed on to be given approval in the European Union following a positive opinion …
NICE rejects Kadcyla
April 23, 2014Sales and Marketing CDF, Cancer, Genentech, Kadcyla, NHS, NICE, Roche
NICE has delivered a severe blow to Roche by rejecting its breast cancer ‘smart bomb’ Kadcyla for NHS use in …
How can ‘innovation’ be defined?
April 14, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, NHS, UK, eric low, innovation, myeloma
Innovation has been and continues to be an important topic of discussion for a number of different stakeholders and disciplines …
‘More patients want Votrient’
April 2, 2014Research and Development, Sales and Marketing Cancer, GSK, Pfizer, Sutent, Votrient
GlaxoSmithKline is looking at patient satisfaction as a potential marketing tool for its kidney cancer drug Votrient, setting up a …
Adaptimmune wins fund payout
March 26, 2014Research and Development, Sales and Marketing Adaptimmune, Cancer, T cell, biomedical, noble, sme
Biotech firm Adaptimmune has been awarded £2.1 million from the UK government’s Biomedical Catalyst Fund, which was set up to …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
